To read the full story, subscribe or sign in.

PDE4 inhibitors claimed by Byk Gulden for airways disorders

March 3, 1999

No Comments

BioWorld Science Respiratory Patents

Today's news in brief

BioWorld

BioWorld briefs for Nov. 29, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November, 29 2023.

Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis

BioWorld Science

Aurinia Pharmaceuticals Inc. has investigated their CD206 ligand AUR-300 as a novel therapeutic agent for systemic sclerosis treatment.

‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

BioWorld

For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...

Historic MHRA exa-cel win bagged, Crispr/Vertex await FDA nod

BioWorld

With a landmark U.K. approval in hand for Casgevy (exagamglogene autotemcel [exa-cel]) to treat sickle cell disease and transfusion-dependent beta thalassemia,...

Upgrade your daily dose of biopharma and medtech news

PDE4 inhibitors claimed by Byk Gulden for airways disorders